Abstract
To the Editor: Winterbauer et al. (N Engl J Med 294:919–921, 1976) present convincing evidence that chrysotherapy may induce diffuse pulmonary injury. We wish to re-emphasize two commonly accepted precautions in the use of chrysotherapy, pertinent to the cases reported. Phenylbutazone and gold sodium thiomalate were given concomitantly in Case 1. A number of authorities123state that pyrazolon-derived drugs (phenylbutazone, oxyphenbutazone) are interdicted during chrysotherapy. Both drugs produce bone-marrow suppression and aplasia, and one drug may enhance the toxic potential of the other.3Furthermore, the causative agent cannot be identified if mucocutaneous lesions develop during combined drug treatment, and.
| Original language | English |
|---|---|
| Pages (from-to) | 506-507 |
| Number of pages | 2 |
| Journal | New England Journal of Medicine |
| Volume | 295 |
| Issue number | 9 |
| DOIs | |
| State | Published - 26 Aug 1976 |
Fingerprint
Dive into the research topics of 'Pulmonary Reaction to Chrysotherapy'. Together they form a unique fingerprint.Cite this
- APA
- Author
- BIBTEX
- Harvard
- Standard
- RIS
- Vancouver